《美股业绩》AbbVie上调全年盈测 新疗法销售劲推高次季收入
艾伯维(AbbVie)(ABBV.US)周四上调年度利润预期,因关节炎药物修美乐(Humira)销量跌幅低于预期,加上新疗法销售强劲,第二季度纯利按年升119%至20.24亿美元,调整后每股盈利为2.91美元,超过分析师平均预期的2.81美元。
期内,收入138.65亿美元,按年跌4.9%。多种仿制药进入美国市场后,修美乐全球销售额按年暴跌25.2%至40.1亿美元,高于预期的39.4亿美元。
艾伯维预期,2023年调整后每股盈利由之前的10.57美元至10.97美元,上调至10.9美元至11.1美元。该股周四升逾5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.